About Ankyrin repeat domain-containing protein 61
Ankyrin repeat domain-containing protein 61 (ANKRD61) is a protein
from Homo sapiens identified by UniProt accession
A6NGH8, 418 residues long.
MolForge cross-references it against 0 known binders and
9 disease associations.
Target properties
| Protein name | Ankyrin repeat domain-containing protein 61 |
| UniProt accession | A6NGH8 |
| Gene | ANKRD61 |
| Organism | Homo sapiens |
| Length | 418 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (9)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.23
- reticulocyte count · score 0.14
- mean corpuscular hemoglobin concentration · score 0.10
- reticulocyte measurement · score 0.10
- Immature Reticulocyte Fraction Measurement · score 0.10
- Red cell distribution width · score 0.07
- mean corpuscular hemoglobin · score 0.02
- blood phosphate measurement · score 0.02
- Crohn's disease · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NGH8-F1 | alphafold | PREDICTED | 84.89 | — |
Amino-acid sequence (418 residues)
MGNITRKGSR DLVVDSAKSL EDGPSAALHS KLYEAIMRED CTTIEVLLRN HPVNQPITIL PNSASNRLLL TQPTESIIPI HLAAKYHKAQ SLLCLLRHGA DPEVRDTTGL TTLNLMLLHW PVTSTTWAKP GNRTHRILTD IQNSSITCLR ILCAHGAQVN TQGEISNKRS PLHLAIAYGC YPVLSILTQN GADVNAINEA SMTPLHMAAN MLNKEMMETL IAYGANVNCA VSSTGNTPLK LAVCTASSKA GRLLGAGVSC IRLLLTHGAK VNAQDYKGQT AIHEACFGGR EAIINLLLEF EANVNILTRN GESPIYMYLQ RSCNVRDTAL LARLLYHTYP LRMTNNQGIL PAGIMLPEFR LLRDTLIKQS QKPLSLQGIC KRNIRNIYGE KYKQHLKQFL PVTIWNSVYC CYDLAYTS
Explore Ankyrin repeat domain-containing protein 61 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets